drugset / Trial / NCT06716853
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
Phase 1/2
Terminated
10 enrolled
Genenta Science
Alira Health · collabArithmos srl · collabOspedale San Raffaele · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with evidence of disease progression following at least two lines of standard of care (SoC) treatments.
Timeline
- Start
- 2024-10-22
- Primary completion
- 2026-01-23
- Completion
- 2026-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Temferon | Cell therapy | — | — |